Biocon Subsidiary Receives U.S. FDA Approval for Everolimus Tablets in Multiple Strengths

1 min read     Updated on 12 Jan 2026, 08:49 AM
scanx
Reviewed by
Riya DScanX News Team
Overview

Biocon Limited's subsidiary Biocon Pharma Limited has received U.S. FDA approval for Everolimus Tablets for Oral Suspension in 2 mg, 3 mg, and 5 mg strengths. The medication is indicated for treating adult and pediatric patients with Tuberous Sclerosis Complex conditions, including SEGA and TSC-associated seizures. The approval strengthens Biocon's vertically integrated drug product portfolio.

29733542

*this image is generated using AI for illustrative purposes only.

Biocon Limited has announced a significant regulatory milestone with its wholly owned subsidiary Biocon Pharma Limited receiving approval from the U.S. Food and Drug Administration (U.S. FDA) for Everolimus Tablets for Oral Suspension. The company notified stock exchanges about this development on January 12, 2026.

FDA Approval Details

The U.S. FDA has approved Biocon Pharma Limited's Abbreviated New Drug Application (ANDA) for Everolimus Tablets for Oral Suspension across three different strengths. The approval encompasses a comprehensive range of dosing options for healthcare providers.

Parameter: Details
Approved Strengths: 2 mg, 3 mg, and 5 mg
Regulatory Authority: U.S. Food and Drug Administration
Application Type: ANDA (Abbreviated New Drug Application)
Subsidiary: Biocon Pharma Limited

Therapeutic Applications

The approved Everolimus Tablets for Oral Suspension serve specific medical indications related to Tuberous Sclerosis Complex (TSC). The medication addresses two distinct patient populations with different age requirements and treatment purposes.

Primary Indications:

  • SEGA Treatment: For adult and pediatric patients aged 1 year and older with Tuberous Sclerosis Complex who have Subependymal Giant Cell Astrocytoma
  • Seizure Management: For adjunctive treatment of adult and pediatric patients aged 2 years and older with TSC-associated partial-onset seizures

Strategic Impact

According to the company's notification to stock exchanges, this FDA approval will further strengthen Biocon's portfolio of vertically integrated drug products. The approval represents an expansion of the company's presence in the U.S. pharmaceutical market through its specialized oncology and rare disease treatment offerings.

The regulatory milestone demonstrates Biocon Pharma Limited's capability to successfully navigate the complex U.S. FDA approval process for specialized therapeutic products. This achievement adds to the company's growing portfolio of approved pharmaceutical products in international markets.

Historical Stock Returns for Biocon

1 Day5 Days1 Month6 Months1 Year5 Years
-2.79%-6.09%-3.82%-1.22%-0.46%-21.70%

Biocon Executive Chairperson Criticizes Andhra Pradesh's 75% Local Employment Mandate

2 min read     Updated on 08 Jan 2026, 05:40 PM
scanx
Reviewed by
Jubin VScanX News Team
Overview

Kiran Mazumdar-Shaw, Executive Chairperson of Biocon Ltd, has criticized the Andhra Pradesh Employment of Local Candidates in Industries/Factories Act, which reserves 75% of private sector jobs for eligible locals. The Act, enacted in 2019 and enforced since October 2019, has sparked debate between advocates of skill-based hiring and supporters of regional employment security. Mazumdar-Shaw argues that such mandates are detrimental to businesses, while critics contend that local job reservations are justified given government incentives provided to companies.

29419796

*this image is generated using AI for illustrative purposes only.

Biocon Executive Chairperson Kiran Mazumdar-Shaw has publicly criticized the Andhra Pradesh government's employment reservation policy, describing it as detrimental to business operations. Her comments address the Andhra Pradesh Employment of Local Candidates in Industries/Factories Act, which mandates 75% job reservation for eligible local candidates in private sector positions.

Policy Details and Implementation

The controversial legislation was enacted in 2019 and has been actively enforced since October 2019, according to a recent RTI reply cited by South First. The Act specifically targets private industries and factories, requiring them to reserve three-quarters of their positions for local workers who meet eligibility criteria.

Policy Parameter: Details
Act Name: Andhra Pradesh Employment of Local Candidates in Industries/Factories Act
Enactment Year: 2019
Enforcement Start: October 2019
Reservation Percentage: 75% for eligible locals
Sector Coverage: Private industries and factories

Mazumdar-Shaw's Position

Responding to social media discussions about the policy, Mazumdar-Shaw expressed strong disagreement with the mandate. "I do not agree with this mandate. I always believe that companies will give preference to locals if they have the required skills," she posted on X. "If not, then such policies are detrimental to businesses."

This stance aligns with her previous comments on similar legislation. The Biocon chief had earlier advocated for exemptions for highly skilled labor when Karnataka's government approved a draft bill mandating 50% reservation for locals in management positions and 70% in non-management categories.

Public Response and Debate

The Executive Chairperson's comments have generated significant discussion on social media platforms. Critics argue that the policy ensures job security for locals without compromising qualification standards. One user questioned why locals should compete with migrants for employment opportunities in their home state, particularly given the incentives provided to companies.

Supporters of regional employment policies contend that reservation systems should exist for both education and employment sectors. They argue that such policies enable cities to develop based on unique local skills and cultural strengths while promoting balanced industrial distribution across regions.

Skills Versus Regional Preferences

The debate highlights fundamental tensions between merit-based hiring and regional employment security. While some social media users support Mazumdar-Shaw's emphasis on skills as the primary hiring criterion, others advocate for mandatory local participation in employment opportunities, especially in regions where companies receive government incentives and support.

The controversy reflects broader policy discussions about balancing business flexibility with local employment generation, particularly in states seeking to attract industrial investment while ensuring benefits reach local populations.

Historical Stock Returns for Biocon

1 Day5 Days1 Month6 Months1 Year5 Years
-2.79%-6.09%-3.82%-1.22%-0.46%-21.70%
More News on Biocon
Explore Other Articles
369.00
-10.60
(-2.79%)